RxDoctor Payments Data

Barry Billington, MD

General Practice · Redding, CANPI 1598774499

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 48 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$267
  • GSK$165
  • AstraZeneca$157
  • Johnson & Johnson$128
  • Lilly USA, LLC$65
  • Novo Nordisk$47
  • plus $180 from 10 others

What the payments were for

  • Food & beverage$97697%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,008 in reported general payments places this provider in the 80th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$917,444
Medicare patients
677
Services billed
13,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate12$105,960
XareltoRivaroxaban299$105,025
EliquisApixaban172$63,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$38,969
JardianceEmpagliflozin87$37,102
OzempicSemaglutide23$35,817
JanuviaSitagliptin Phosphate41$25,770
GlyxambiEmpagliflozin/Linagliptin34$23,195
FarxigaDapagliflozin Propanediol60$23,161
Tresiba Flextouch U-100Insulin Degludec85$20,296
Breo ElliptaFluticasone/Vilanterol29$18,017
ZenpepLipase/Protease/Amylase25$17,167
RexultiBrexpiprazole19$13,623
Divalproex Sodium129$11,066
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$10,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$128$105,025299 claims
PfizerEliquis$21$63,348172 claims
GSKTrelegy Ellipta, Breo Ellipta$165$56,98684 claims
Novo NordiskOzempic$47$35,81723 claims
MerckJanuvia$13$25,77041 claims
AstraZenecaFarxiga$157$23,16160 claims
Otsuka America Pharmaceutical, Inc.Rexulti$27$13,62319 claims
Astellas Pharma US IncMyrbetriq$20$8,23235 claims
NovartisEntresto$17$4,81714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 12,963 general practice providers in California.

Other general practice in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →